April 26-29, 2026

International Oncolytic Virus Conference (IOVC)

Stephen Russell, M.D., Ph.D., Vyriad President and Chief Executive Officer, presented “Oncolytic Virotherapy Expands and Reprograms T Cells into CAR-T Cells Within the Tumor Microenvironment”, Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer presented “ A Phase 1 Clinical Trial to Evaluate Intravenous VSV-IFNβ-NIS in Combination with Cemiplimab and Ipilimumab for Relapsed Peripheral T-Cell Lymphoma” and Luke Russell, Ph.D., Vyriad Executive Vice President attended the International Oncolytic Virus Conference in Reykjavik, Iceland.